1. Home
  2. RLYB

RLYB

Rallybio Corporation

Logo Rallybio Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 2:31pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Founded: 2018 Country:
United States
United States
Employees: N/A City: NEW HAVEN
Market Cap: 112.7M IPO Year: 2021
Target Price: $10.42 AVG Volume (30 days): 1.6M
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.84 EPS Growth: N/A
52 Week Low/High: $1.23 - $9.14 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: